ZEVRA THERAPEUTICS INC. - COMMON STOCK

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

11 مارس 2025 16:05:15 بحسب Nasdaq GlobeNewswire

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,’ to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

28 فبراير 2025 07:30:00 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

27 فبراير 2025 07:30:59 بحسب Nasdaq GlobeNewswire

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

26 فبراير 2025 09:46:16 بحسب Nasdaq GlobeNewswire

Zevra to Participate at Upcoming Investor Conferences

24 فبراير 2025 16:02:00 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

30 يناير 2025 07:30:00 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics to Participate at Upcoming Investor Conferences

29 يناير 2025 16:05:00 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

17 ديسمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics Announces Organizational Changes

06 ديسمبر 2024 17:00:00 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics to Participate at Upcoming Investor Conferences

26 نوفمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

21 نوفمبر 2024 16:51:59 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

12 نوفمبر 2024 16:05:01 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

11 نوفمبر 2024 16:36:41 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

06 نوفمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

31 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

10 أكتوبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders

09 أكتوبر 2024 09:00:00 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

24 سبتمبر 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

20 سبتمبر 2024 12:08:07 بحسب Nasdaq GlobeNewswire

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

06 سبتمبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire